umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Identification of a small molecule that stabilizes lipoprotein lipase in vitro and lowers triglycerides in vivo
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Fysiologisk kemi.
Umeå universitet, Teknisk-naturvetenskapliga fakulteten, Kemiska institutionen.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Fysiologisk kemi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap. Tallinn University of Technology, Department of Chemistry, Tallinn, Estonia.
Visa övriga samt affilieringar
2014 (Engelska)Ingår i: Biochemical and Biophysical Research Communications - BBRC, ISSN 0006-291X, E-ISSN 1090-2104, Vol. 450, nr 2, s. 1063-1069Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Patients at increased cardiovascular risk commonly display high levels of plasma triglycerides (TGs) levels, elevated LDL cholesterol, small dense LDL particles and low levels of HDL-cholesterol. Many remain at high risk even after successful statin therapy, presumably because TG levels remain high. Lipoprotein lipase (LPL) maintains TG homeostasis in blood by hydrolysis of TG-rich lipoproteins. Efficient clearance of TGs is accompanied by increased levels of HDL-cholesterol and decreased levels of small dense LDL. Given the central role of LPL in lipid metabolism we sought to find small molecules that could increase LPL activity and serve as starting points for drug development efforts against cardiovascular disease. Using a small molecule screening approach we have identified small molecules that can protect LPL from inactivation by the controller protein angiopoietin-like protein 4 during incubations in vitro. One of the selected compounds, 50F10, was directly shown to preserve the active homodimer structure of LPL, as demonstrated by heparin-Sepharose chromatography. This compound tended to reduce fasting TG levels in normal rats. On injection to hypertriglyceridemic apolipoprotein A-V deficient mice the compound ameliorated the postprandial response after an olive oil gavage. This compound is a potential lead compound for the development of drugs that could reduce the residual risk associated with elevated TGs in dyslipidemia.

Ort, förlag, år, upplaga, sidor
Elsevier, 2014. Vol. 450, nr 2, s. 1063-1069
Nyckelord [en]
Lipoprotein lipase, Angiopoietin-like protein 4, Hypertriglyceridemia, Lipoprotein metabolism, Cardiovascular disease, Small molecule screening
Nationell ämneskategori
Kardiologi
Identifikatorer
URN: urn:nbn:se:umu:diva-91689DOI: 10.1016/j.bbrc.2014.06.114ISI: 000339861200023PubMedID: 24984153OAI: oai:DiVA.org:umu-91689DiVA, id: diva2:737688
Forskningsfinansiär
VetenskapsrådetVINNOVAKnut och Alice Wallenbergs StiftelseCarl Tryggers stiftelse för vetenskaplig forskning Tillgänglig från: 2014-08-13 Skapad: 2014-08-13 Senast uppdaterad: 2018-06-07Bibliografiskt granskad
Ingår i avhandling
1. Endogenous and exogenous factors affecting lipoprotein lipase activity
Öppna denna publikation i ny flik eller fönster >>Endogenous and exogenous factors affecting lipoprotein lipase activity
2014 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Individuals with high levels of plasma triglycerides are at high risk to develop cardiovascular disease (CVD), currently one of the major causes of death worldwide. Recent epidemiological studies show that loss-of-function mutations in the APOC3 gene lower plasma triglyceride levels and reduce the incidence of coronary artery disease. The APOC3 gene encodes for apolipoprotein (APO) C3, known as an inhibitor of lipoprotein lipase (LPL) activity. Similarly, a common gain-of-function mutation in the LPL gene is associated with reduced risk for CVD.

LPL is central for the metabolism of lipids in blood. The enzyme acts at the endothelial surface of the capillary bed where it hydrolyzes triglycerides in circulating triglyceride-rich lipoproteins (TRLs) and thereby allows uptake of fatty acids in adjacent tissues. LPL activity has to be rapidly modulated to adapt to the metabolic demands of different tissues. The current view is that LPL is constitutively expressed and that the rapid modulation of the enzymatic activity occurs by some different controller proteins. Angiopoietin-like protein 4 (ANGPTL4) is one of the main candidates for control of LPL activity. ANGPTL4 causes irreversible inactivation through dissociation of the active LPL dimer to inactive monomers. Other proteins that have effects on LPL activity are the APOCs which are surface components of the substrate TRLs. APOC2 is a well-known LPL co-factor, whereas APOC1 and APOC3 independently inhibit LPL activity.

Given the important role of LPL for triglyceride homeostasis in blood, the aim of this thesis was to find small molecules that could increase LPL activity and serve as lead compounds in future drug discovery efforts. Another aim was to investigate the molecular mechanisms for how APOC1 and APOC3 inhibit LPL activity.

Using a small molecule screening library we have identified small molecules that can protect LPL from inactivation by ANGPTL4 during incubations in vitro. Following a structure-activity relationship study we have synthesized lead compounds that more efficiently protect LPL from inactivation by ANGPTL4 in vitro and also have dramatic triglyceride-lowering properties in vivo. In a separate study we show that low concentrations of fatty acids possess the ability to prevent inactivation of LPL by ANGPTL4 under in vitro conditions.

With regard to APOC1 and APOC3 we demonstrate that when bound to TRLs, these apolipoproteins prevent binding of LPL to the lipid/water interface. This results in decreased lipolysis and in an increased susceptibility of LPL to inactivation by ANGPTL4. We demonstrate that hydrophobic amino acid residues that are centrally located in the APOC3 molecule are critical for attachment of this protein to lipid emulsion particles and consequently for inhibition of LPL activity.

In summary, this work has identified a lead compound that protects LPL from inactivation by ANGPTL4 in vitro and lowers triglycerides in vivo. In addition, we propose a molecular mechanism for inhibition of LPL activity by APOC1 and APOC3.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå University, 2014. s. 56
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1669
Nyckelord
LPL, APOC1, APOC2, APOC3, ANGPTL4, enzyme inactivation, lipoprotein metabolism, triglycerides, fatty acids, hypertriglyceridemia, CVD, small molecule screening, structure-activity relationship
Nationell ämneskategori
Cell- och molekylärbiologi
Forskningsämne
medicin, hjärt- och kärlforskning
Identifikatorer
urn:nbn:se:umu:diva-91662 (URN)978-91-7601-115-7 (ISBN)
Disputation
2014-08-27, NUS - Norrlands universitetssjukhus, Sal E04, Byggnad 6E, Umeå Universitet, Umeå, 14:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2014-08-15 Skapad: 2014-08-13 Senast uppdaterad: 2018-06-07Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Larsson, MikaelCaraballo, RémiEricsson, MadeleneLookene, AivarEnquist, Per-AndersElofsson, MikaelOlivecrona, Gunilla

Sök vidare i DiVA

Av författaren/redaktören
Larsson, MikaelCaraballo, RémiEricsson, MadeleneLookene, AivarEnquist, Per-AndersElofsson, MikaelOlivecrona, Gunilla
Av organisationen
Fysiologisk kemiKemiska institutionenInstitutionen för medicinsk biovetenskapUmeå Centre for Microbial Research (UCMR)
I samma tidskrift
Biochemical and Biophysical Research Communications - BBRC
Kardiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 528 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf